Advertisement
BIO vs DHR
Which Stock Would AI Choose? Bio-Rad Laboratories (BIO) vs. Danaher Corporation (DHR) Stock Comparison
Key Takeaways
- BIO (Bio-Rad Laboratories) has posted strong recent momentum, but its premium valuation and soft life sciences demand temper the bull case.
- DHR (Danaher Corporation) is a far larger, more diversified tools and diagnostics platform with a recovering bioprocessing business.
- Bio-Rad is heavily dependent on its Clinical Diagnostics segment, which represented roughly 60% of 2025 revenue.
- Danaher's recent catalysts include improving bioprocessing orders, the Masimo acquisition, and a new artificial intelligence collaboration with NVIDIA.
- Both stocks face uneven end-market demand, but Danaher's broader diversification and stronger margin profile give it a steadier trend profile.
Introduction
Investors screening the life sciences and diagnostics space frequently weigh BIO against DHR, two companies with overlapping end markets but very different scale and structure. Bio-Rad Laboratories is a focused provider of life science research and clinical diagnostics products, while Danaher Corporation is a diversified scientific technology conglomerate spanning biotechnology, life sciences, and diagnostics. This stock comparison is relevant for traders assessing relative momentum and for longer-horizon investors evaluating market positioning, growth durability, and risk. Because the two names respond to similar demand cycles differently, a side-by-side review can clarify which profile better suits a given strategy in the current environment.
BIO Overview and Recent Performance
BIO, Bio-Rad Laboratories, develops and sells life science research tools and clinical diagnostics products. Its recurring-revenue Clinical Diagnostics business—quality controls, diabetes testing, and blood typing—provides stability, while its Life Science segment, anchored by droplet digital PCR (ddPCR, a precise DNA quantification technology), drives its growth narrative.
In recent weeks, BIO shares have gained roughly 19%, aided by ddPCR momentum and steadier diagnostics demand. Instrument revenue in digital PCR has grown more than 20% year over year, and the company's Stilla acquisition is expanding its digital PCR portfolio and supporting margins. However, Life Science demand remains soft, with soft academic and government funding and a double-digit decline in China. Management also cited a Middle East conflict headwind of about $11 million per quarter. Bio-Rad guided 2026 currency-neutral revenue to a decline of roughly 3% to growth of about 0.5%, with a non-GAAP operating margin of 10% to 12%. The stock trades near 40 times forward earnings, well above its industry, leaving less room for execution misses.
DHR Overview and Recent Performance
DHR, Danaher Corporation, operates three segments—Biotechnology, Life Sciences, and Diagnostics—and applies its Danaher Business System, a continuous-improvement operating framework, to acquire and strengthen businesses. Its roughly $160 billion market capitalization and sticky consumables revenue base distinguish it from smaller, more narrowly focused peers.
Recent market activity reflects a gradual but uneven recovery. In the second quarter of 2026, revenue rose 5.5% to about $6.3 billion and core revenue grew 3%, with management describing its life sciences businesses as delivering their strongest quarter in several years. Bioprocessing demand has firmed, with equipment orders rising more than 30% in the first quarter. Danaher also completed its roughly $9.8 billion acquisition of Masimo, a patient-monitoring and pulse oximetry company, in June, and in October announced an AI collaboration with NVIDIA focused on autonomous science. The company raised its 2026 adjusted earnings guidance, and shares sit near the upper end of their 52-week range, though valuation remains a point of debate.
Trending AI Robots
For traders who prefer a systematic approach to this type of stock comparison, Tickeron's Trending AI Robots page offers a curated view of its AI trading bots. Tickeron hosts hundreds of AI Trading Bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance history, and set of instruments. Because not every bot suits every market, only those best aligned with current conditions are featured in the Trending section. This curated list lets traders quickly scan bots that have demonstrated relevance to prevailing market regimes rather than sifting through the full catalog. Explore the Trending AI Robots page to see which automated strategies are currently in focus.
Head-to-Head Comparison
The clearest contrast between these two names is scale and diversification. DHR spans biotechnology, life sciences, and diagnostics, smoothing cyclical swings across any single end market. BIO is more concentrated, with Clinical Diagnostics providing recurring revenue but Life Science exposure leaving it more sensitive to academic and biopharma funding cycles.
Growth drivers also differ. Bio-Rad's case rests on ddPCR adoption, the Stilla integration, and cost-savings execution. Danaher's rests on a bioprocessing recovery, the Masimo integration, and its disciplined acquisition engine. On momentum, Bio-Rad has outperformed recently, but that strength coincides with a materially higher forward multiple. On risk, Bio-Rad carries geopolitical and funding headwinds plus a premium valuation, while Danaher faces integration and financing considerations tied to Masimo and a slower-than-hoped diagnostic rebound. Market sentiment leans more clearly positive on Danaher, which carries a consensus "Strong Buy" analyst rating, whereas Bio-Rad is more mixed.
Tickeron AI Verdict
On the factors a systematic model would likely weight—trend consistency, diversification, margin quality, and identifiable catalysts—DHR currently presents the more balanced profile. Its broader revenue base, recovering bioprocessing orders, and established operating framework suggest a steadier, more durable trend than BIO's narrower, momentum-driven setup. That said, BIO's recent outperformance and digital PCR growth cannot be dismissed, particularly for shorter-horizon traders. The more probable AI-favored outcome leans toward Danaher for stability and risk-adjusted positioning, while Bio-Rad remains a higher-beta candidate dependent on continued execution.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIO is a StrongBuy and DHR is a StrongBuy.
BIO in upward trend: 10-day moving average crossed above 50-day moving average on November 04, 2026
The 10-day moving average for BIO crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on BIO as a result. In 69 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
The Moving Average Convergence Divergence (MACD) for BIO just turned positive on October 23, 2026. Looking at past instances where BIO's MACD turned positive, the stock continued to rise in 36 of 50 cases over the following month. The odds of a continued upward trend are 72%.
BIO moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +5.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIO advanced for three days, in 194 of 299 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
BIO broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BIO entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 15 (best 1 - 100 worst), indicating outstanding price growth. BIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 87 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.422) is normal, around the industry mean (4.142). P/E Ratio (46.363) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (4.006) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.940) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Momentum Indicator for DHR turns positive, indicating new upward trend
DHR saw its Momentum Indicator move above the 0 level on November 09, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 90 similar instances where the indicator turned positive. In 57 of the 90 cases, the stock moved higher in the following days. The odds of a move higher are at 63%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +2.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where DHR advanced for three days, in 179 of 322 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
The Aroon Indicator entered an Uptrend today. In 111 of 195 cases where DHR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 57%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Moving Average Convergence Divergence Histogram (MACD) for DHR turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 30 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 64%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DHR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 59%.
DHR broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.078) is normal, around the industry mean (67.298). P/E Ratio (40.824) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (1.361) is also within normal values, averaging (3.473). Dividend Yield (0.007) settles around the average of (0.002) among similar stocks. P/S Ratio (5.900) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 18 (best 1 - 100 worst), indicating outstanding price growth. DHR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 77 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DHR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
BIO | DHR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 30 | 29 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 90 Overvalued | 15 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 87 | 77 | |
PRICE GROWTH RATING 1..100 | 15 | 18 | |
P/E GROWTH RATING 1..100 | 2 | 54 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DHR's Valuation (15) in the Medical Specialties industry is significantly better than the same rating for BIO (90). This means that DHR’s stock grew significantly faster than BIO’s over the last 12 months.
DHR's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as BIO (100). This means that DHR’s stock grew similarly to BIO’s over the last 12 months.
DHR's SMR Rating (77) in the Medical Specialties industry is in the same range as BIO (87). This means that DHR’s stock grew similarly to BIO’s over the last 12 months.
BIO's Price Growth Rating (15) in the Medical Specialties industry is in the same range as DHR (18). This means that BIO’s stock grew similarly to DHR’s over the last 12 months.
BIO's P/E Growth Rating (2) in the Medical Specialties industry is somewhat better than the same rating for DHR (54). This means that BIO’s stock grew somewhat faster than DHR’s over the last 12 months.
| BIO | DHR | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 1 day ago 84% | 1 day ago 61% |
| Momentum ODDS (%) | 1 day ago 73% | 1 day ago 63% |
| MACD ODDS (%) | 1 day ago 72% | 1 day ago 64% |
| TrendWeek ODDS (%) | 1 day ago 66% | 1 day ago 57% |
| TrendMonth ODDS (%) | 1 day ago 69% | 1 day ago 58% |
| Advances ODDS (%) | 3 days ago 65% | 2 days ago 56% |
| Declines ODDS (%) | 1 day ago 69% | 10 days ago 59% |
| BollingerBands ODDS (%) | 1 day ago 70% | 1 day ago 59% |
| Aroon ODDS (%) | 1 day ago 68% | 1 day ago 57% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIO’s FA Score shows that 2 FA rating(s) are green while DHR’s FA Score has 2 green FA rating(s).
- BIO’s FA Score: 2 green, 3 red.
- DHR’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIO’s TA Score shows that 5 TA indicator(s) are bullish while DHR’s TA Score has 3 bullish TA indicator(s).
- BIO’s TA Score: 5 bullish, 4 bearish.
- DHR’s TA Score: 3 bullish, 4 bearish.
Price Growth
BIO (@Medical/Nursing Services) experienced а +3.09% price change this week, while DHR (@Medical Specialties) price change was +2.61% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.89%. For the same industry, the average monthly price growth was -4.69%, and the average quarterly price growth was -1.76%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -4.92%. For the same industry, the average monthly price growth was -5.08%, and the average quarterly price growth was +38.31%.
Reported Earning Dates
BIO is expected to report earnings on Feb 18, 2027.
DHR is expected to report earnings on Feb 03, 2027.
Industries' Descriptions
@Medical/Nursing Services (-2.89% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (-4.92% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
BIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, BIO has been closely correlated with A. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if BIO jumps, then A could also see price increases.
DHR and
Correlation & Price change
A.I.dvisor indicates that over the last year, DHR has been closely correlated with TMO. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if DHR jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To DHR | 1D Price Change % | ||
|---|---|---|---|---|
| DHR | 100% | -0.34% | ||
| TMO - DHR | 73% Closely correlated | -0.07% | ||
| RGEN - DHR | 68% Closely correlated | -0.78% | ||
| BIO - DHR | 64% Loosely correlated | -0.12% | ||
| A - DHR | 60% Loosely correlated | -0.52% | ||
| BRKR - DHR | 58% Loosely correlated | +0.27% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| OILU | 47.62 | 2.60 | +5.78% |
| MicroSectors Oil & Gas Exp. & Prod. 3x Leveraged ETN (OILU) | |||
| FAI | 50.72 | 1.35 | +2.73% |
| First Trust Exchange-Traded Fund II | |||
| JHEM | 37.64 | 0.69 | +1.87% |
| John Hancock Multifactor Emerging Markets ETF (JHEM) | |||
| UUPP | 25.17 | N/A | N/A |
| Principal CLO ETF (UUPP) | |||
| VCSH | 77.47 | -0.07 | -0.09% |
| Vanguard Short-Term Corporate Bond ETF (VCSH) | |||